Pith. sign in

REVIEW 3 major objections 3 minor 202 references

Advancing Digital Precision Medicine for Chronic Fatigue Syndrome through Longitudinal Large-Scale Multi-Modal Biological Omics Modeling with Machine Learning and Artificial Intelligence

T0 review · 3 major / 3 minor · reviewed 2026-08-06 · deepseek-v4-flash

Challenge this review Re-run · record.json Download PDF Read on arXiv ↗

Pith's one-line read An explainable deep network reconstructs ME/CFS symptoms from multi-omics and classifies patients with 91% AUC.

desk verdict A valuable longitudinal multi-omics resource and a sensible multi-task modeling idea, but the headline 91% AUC is likely inflated by sample-level cross-validation and needs a patient-level reanalysis before it can be trusted. read the letter →

arxiv 2506.15761 v1 pith:JU7PTNRM submitted 2025-06-18 q-bio.GN cs.LG

Ruoyun Xiong This is my paper · ORCID
classification q-bio.GNcs.LG
keywords ME/CFSmulti-omicsdeeplearningexplainableAIsymptomreconstructionbiomarkerdiscoverygutmicrobiomemetabolomics
verification ladder T0 review T1 audit T2 compute T3 formal

The pith

A machine-rendered reading of the paper's core claim, the machinery that carries it, and where it could break.

The reading

This thesis reports a deep-learning framework, BioMapAI, that connects multiple biological omics layers—gut metagenomics, plasma metabolome, immune cell profiles, and blood labs—to a matrix of twelve clinical symptom scores in a longitudinal cohort of 249 participants followed for up to four years. The central claim is that the model's predicted symptom scores separate ME/CFS patients from healthy controls with 91% AUC, outperforming gradient boosting, support vector machines, and a standard deep network, and that it generalizes to independent external cohorts better than those baselines. The same model yields both disease-level and symptom-level biomarkers and produces the first connectivity map of microbiome-immune-metabolome interactions in health and disease. If correct, the work shows that a heterogeneous chronic illness can be characterized by linking many biological measurements to many clinical outcomes at once, rather than to a single diagnosis.

What carries the argument

The central object is the BioMapAI architecture: a deep neural network whose hidden layers are split into two shared general-pattern layers and a third layer of parallel sub-networks, one per clinical outcome, so the model learns both disease-wide and symptom-specific representations. This design lets a single model map high-dimensional omics inputs to a mixed-type outcome matrix of 12 clinical scores, with loss functions chosen per outcome. Explainability comes from SHAP values computed on reconstructed per-symptom sub-models, and the connectivity map is built separately with WGCNA co-expression modules and Spearman correlations between modules across omics layers.

What would settle it

Re-run the five-fold cross-validation with all timepoints from each participant assigned to the same fold (grouped or leave-one-participant-out), and compare the AUC to the reported 91%. If the grouped AUC drops substantially toward chance, the in-cohort result is inflated by within-participant leakage rather than reflecting true disease classification.

Watch

Extended reading notes

Core claim

BioMapAI is a fully connected neural network with two shared hidden layers (64 and 32 nodes) followed by a parallel layer of 12 outcome-specific sub-networks, one per clinical score, with each output assigned its own loss function. Trained with five-fold cross-validation on five omics inputs, the network reconstructs the distribution of the twelve symptom scores and, through an auxiliary classification layer, distinguishes ME/CFS from healthy controls with 91% AUC using integrated multi-omics. Immune profiling is the strongest single modality (80% AUC), followed by KEGG gene abundance (78%) and blood measures (71%). In external cohorts, BioMapAI outperforms GBDT and a standard DNN, supporting the paper's claim that connecting omics to symptoms improves generalizability. The paper further identifies shared disease-specific biomarkers (e.g., increased B cells and CD4 naive T cells, Dysosmobacter welbionis, bile acid changes) and symptom-specific biomarkers (e.g., Faecalibacterium prausnitzii showing a biphasic relationship with pain), and describes how healthy microbiome-immune-metabolome networks, including butyrate, BCAA, and tryptophan pathways, become dysbiotic in patients.

Load-bearing premise

The headline 91% AUC assumes that repeated samples from the same participant are effectively independent, so that five-fold cross-validation without participant-level grouping does not let the model memorize patient-specific signatures and inflate performance.

Editorial extensions

If this is right

  • Multi-omics profiles can reconstruct the twelve clinical symptom scores well enough that predicted scores serve as a disease classifier with 91% AUC.
  • Immune profiling is the most informative single modality for most symptoms, while the gut microbiome is the best predictor of gastrointestinal, emotional, and sleep scores.
  • The model's architecture and SHAP decoding separate disease-specific from symptom-specific biomarkers, enabling per-symptom biomarker discovery in heterogeneous chronic disease.
  • Healthy microbiome-immune-metabolome networks are established as a baseline, and their dysregulation in ME/CFS—loss of butyrate and BCAA interactions, gain of inflammatory gamma-delta T and MAIT cell connections—points to testable targets for intervention.
  • The same framework is portable to other heterogeneous chronic conditions, including long COVID, by swapping the input omics matrix and the output symptom matrix.

Reading between the lines

Editorial extensions of the paper, not claims the author makes directly.

  • If the 91% AUC survives participant-grouped cross-validation, the strongest immediate use is not diagnosis but patient stratification: predicted symptom scores could guide personalized symptom management even without a biomarker-based diagnostic test.
  • The multi-task architecture suggests a general recipe for other omics studies of heterogeneous disease: predicting the full symptom vector rather than a single label may yield richer biomarkers and better external generalizability—an effect that could be tested on public single-cohort datasets.
  • The reported loss of butyrate/BCAA interactions with regulatory T cells implies a concrete experiment: short-term butyrate or BCAA supplementation in a small ME/CFS cohort should shift the SHAP-predicted pain, GI, and fatigue scores if the connectivity map reflects causal biology.
  • The absence of strong temporal signals over 3-4 years may indicate that baseline omics capture a stable trait-like disease state; testing this requires longer follow-up or event-based modeling of symptom flares rather than yearly averages.
Share X Bluesky LinkedIn Reddit HN

Editorial analysis

A structured set of objections, weighed in public.

Desk editor's note, referee report, and a circularity audit.

Referee Report

3 major / 3 minor

Summary. The thesis chapter presents a longitudinal multi-omics cohort study of ME/CFS (153 patients, 96 healthy controls, 515 timepoints) and introduces BioMapAI, an explainable multi-task deep neural network that maps omics matrices to 12 clinical symptom scores and then uses the predicted scores for binary disease classification. The paper claims that omics-derived predicted scores achieve a 91% AUC in distinguishing ME/CFS patients from healthy controls within the cohort, that BioMapAI outperforms LR, SVM, GDBT, and a standard DNN, and that it validates on four external cohorts with accuracies between 58% and 72%. The authors further use WGCNA and SHAP to identify disease- and symptom-specific biomarkers and to construct microbiome-immune-metabolome interaction networks, proposing mechanistic hypotheses involving butyrate, BCAA, tryptophan, benzoate, and mucosal immune cells.

Significance. If the central performance claims were established, the work would be valuable: the longitudinal multi-omics dataset is rich, the multi-output neural architecture is a sensible response to disease heterogeneity, the code and trained models are promised on GitHub, and the external cohort attempts go beyond most single-cohort studies. The confounder analyses (MaAsLin2, residual adjustment for immune and metabolome data) and the use of SHAP for interpretability are concrete strengths. However, the headline 91% AUC and the claimed superiority over baselines rest on a cross-validation procedure that is not shown to be participant-stratified in a repeated-measures design, and the external validation is quantitatively weak, with several accuracies near chance and feature overlaps as low as 19%. The microbial metabolite inference in Chapter 1 also has a circularity concern. These issues are load-bearing for the central claims, so the manuscript needs substantive revision before its main conclusions can be accepted.

major comments (3)
  1. [Chapter 2, Methods, 'Cross-Validation and Model Training'] The five-fold cross-validation used to produce the 91% AUC is described only as 'a robust 5-fold cross-validation' in the main text and in the Methods section. The cohort contains 515 timepoints from 249 participants, so repeated samples from the same individual are almost certainly present in multiple folds if splitting is performed on samples rather than on participants. Because both the omics features and the 12 clinical scores are strongly person-specific, sample-level folds allow the model to memorize patient identity, inflating the symptom reconstruction accuracy and hence the downstream binary classification AUC of the optional ScoreLayer. The Discussion acknowledges that the model was 'trained on < 500 samples with fivefold cross-validation' without stating that folds were grouped by participant. The authors must either demonstrate that cross-validation was stratified by participant (e.g., groupKFold) or re-run the entire evaluation with participant-level splitting and report the resulting AUCs and baseline comparisons. Without this, the central 'state-of-the-art precision' claim is not established.
  2. [Chapter 2, Results, 'External Validation' and Methods, 'External Validation with Independent Dataset'] The external validation protocol zero-imputes all missing features to align external datasets to the BioMapAI feature set. With the Che metabolome cohort featuring only 19% feature overlap, and the Germain cohort 79%, the test effectively runs the model on matrices that are mostly zeros, which can attenuate performance in either direction and makes the reported accuracies (59% and 68%) difficult to interpret. Moreover, the claim that 'BioMapAI significantly surpassed GDBT and DNN in external cohort validation' is not supported by any statistical test, confidence interval, or repeated subsampling of the external data; the accuracies of 58-72% are also close to chance for a binary classification. The authors should report the external validation with only overlapping features (or a principled imputation), include uncertainty estimates, and test whether the difference from baselines is statistically significant.
  3. [Chapter 1, Methods, 'Gut metabolic status prediction' and Results, 'Gut and plasma butyrate is reduced in early-stage…] The MCMC-based inference of gut isobutyrate (Figure 6B) accepts simulation steps only when the simulated growth rate correlates with the metagenomic species abundance profile (Pearson ρ > 0.6). This means the predicted gut metabolome is not independent of the species abundance differences used to define the patient groups. The subsequent claim that 'inferred concentrations of isobutyrate were significantly decreased in ME/CFS' is therefore not an independent confirmation of reduced gut butyrate; it is a re-statement of the species-level differences already used to calibrate the simulation. The authors should either present the species-abundance-based result as the primary evidence, or recalibrate the MCMC without the abundance-correlation acceptance criterion and show that the predicted butyrate difference still holds.
minor comments (3)
  1. [Chapter 2, Methods, 'BioMapAI'] The learning rate is stated as 0.01 in the initial description ('The learning rate was set to 0.01') and then as 0.0005 in the 'Cross-Validation and Model Training' section ('a learning rate of 0.0005, optimized through grid search'). Please clarify which value was used for the reported models or describe the grid search that led to the final choice.
  2. [Chapter 2, Figure 2E] The external validation bar chart reports accuracies without error bars or sample sizes per cohort in the main figure. Adding bootstrapped confidence intervals and the number of test samples would make the comparison with baselines interpretable.
  3. [General] There are several typos and formatting inconsistencies, for example 'intergrading' in Chapter 1 ('our 'omics workflows could be one of the guiding frameworks to intergrading'), 'in the in the TissueLyser' in Chapter 2 Methods, and the inconsistent use of 'GDBT' versus 'GBDT' across the thesis. A careful proofread is needed.

Circularity Check

1 steps flagged · score 5.0 of 10

Inferred gut isobutyrate is constrained to match the metagenomic species profile that already showed butyrate depletion; the central BioMapAI classification claim is not circular.

  1. fitted input called prediction [Chapter 1 Methods, 'Gut metabolic status prediction'; reported in Results, 'Gut and plasma butyrate is reduced in early-stage disease and is associated with host abnormal physiology']
    "In each step, we sampled one metabolite and used the Flux balance analysis to model reaction flux with a slight change of the target metabolites and accepted the step only if the probed growth rate is correlated with the species relative abundance. Samples were first subjected to 100,000 search steps, and 100,000 steps were subsequently added until a high Pearson correlation (ρ > 0.6) with the target metagenomic abundance profile was achieved."

    The MCMC metabolite 'prediction' is accepted only when the simulated biomass profile correlates with the observed species relative abundance at ρ > 0.6, and the final output averages the iterations with the highest such correlation. The inferred gut isobutyrate is therefore constructed to track the metagenomic species profile. Because the same species profile already showed depletion of butyrate producers (e.g., Roseburia, F. prausnitzii) and butanoate-pathway genes in ME/CFS, the reported decrease in predicted isobutyrate is not an independent measurement; it is a transformed restatement of the input species differences.

full rationale

The main BioMapAI derivation chain in Chapter 2 is self-contained: omics matrices are inputs, twelve clinical scores are predicted by a neural network, and an auxiliary layer maps the predicted scores to a binary disease label. The reported 91% AUC is a genuine supervised-learning evaluation, not an identity with the inputs, though the lack of participant-level grouping in the stated five-fold cross-validation is a correctness risk rather than a circularity. External validation with zero-imputed missing features is a methodological hazard but does not reduce to the model's own inputs by definition. The one circularity-adjacent step is the Chapter 1 MCMC gut-metabolite inference, whose acceptance criterion forces correlation with the species abundance profile, so its group comparison is partly forced by construction. Because this inferred metabolite is a supporting element of the butyrate story rather than the basis of the state-of-the-art classification claim, the overall circularity is partial and localized rather than a collapse of the central derivation.

Assumptions & free parameters 5 free parameters · 5 assumptions · 0 invented entities

The central claims rest on a set of modeling choices and domain assumptions: the completeness of the 12 symptom scores, the validity of cross-sectional disease-duration comparisons, the reliability of MCMC-predicted gut metabolites, the equivalence of zero-imputed external features, and the independence of repeated samples in cross-validation. No new physical entities are introduced.

free parameters (5)
  • BioMapAI hyperparameters (nodes 64/32/8, dropout 0.5, L2 lambda=0.008, learning rate 0.0005, 500 epochs) = 64/32/8 nodes, 0.5 dropout, 0.008 L2, 5e-4 learning rate, 500 epochs
    Chosen by grid search on the training data; classification AUC and symptom reconstruction MSE depend on these values.
  • Disease-specific biomarker cutoff = 75%
    Features appearing among top contributors in 75% of the 12 symptom models are labeled disease-specific; this threshold is arbitrary and changes biomarker categorization.
  • WGCNA soft-thresholding powers = species=6, KEGG=7, immune=5, metabolome=6
    Selected per dataset to construct modules; the connectivity map depends on these choices.
  • MAMBO MCMC acceptance threshold = Pearson rho > 0.6
    Gut metabolome predictions are accepted only if simulated biomass correlates with metagenomic species abundance; this couples predicted metabolites to the input species profile.
  • Feature prevalence filters = species avg rel abundance > 1e-4; genes prevalence > 20%; metabolites present in > 50% samples
    Feature inclusion thresholds affect downstream models and biomarker lists.
assumptions (5)
  • domain assumption The 12 clinical scores derived from questionnaires and clinical tests fully capture the relevant ME/CFS phenotype space.
    Invoked in Chapter 2 Cohort Overview and Clinical Metadata; if scores miss key symptoms or are noisy, symptom reconstruction and classification inherit that error.
  • domain assumption Cross-sectional short-term versus long-term cohorts can stand in for disease progression.
    Chapter 1 Conclusion acknowledges the design is cross-sectional and survival bias is possible; the progression narrative rests on this assumption.
  • domain assumption MAMBO and MCMC produce valid estimates of gut metabolite concentrations from metagenomes without matched fecal metabolomics.
    Chapter 1 Methods 'Gut metabolic status prediction'; the predicted isobutyrate decrease is used as evidence of reduced gut butyrate.
  • ad hoc to paper Zero-imputation of unmeasured features preserves cross-cohort comparability in external validation.
    Chapter 2 Methods 'External Validation'; missing features in external cohorts are set to zero, which assumes absence equals zero abundance and can dominate predictions when feature overlap is low.
  • ad hoc to paper Repeated samples from the same participant can be treated as independent in five-fold cross-validation.
    Methods 'Cross-Validation and Model Training' does not state participant-level splits; the 91% AUC assumes no patient-level leakage.

how reviews work

0 comments
Cite this review

Pith. "Pith review of Advancing Digital Precision Medicine for Chronic Fatigue Syndrome through Longitudinal Large-Scale Multi-Modal Biological Omics Modeling with Machine Learning and Artificial Intelligence." pith.science (2026). https://pith.science/paper/JU7PTNRM

@misc{pith2026250615761,
  author       = {Pith},
  title        = {Pith review of: Advancing Digital Precision Medicine for Chronic Fatigue Syndrome through Longitudinal Large-Scale Multi-Modal Biological Omics Modeling with Machine Learning and Artificial Intelligence},
  year         = {2026},
  howpublished = {\url{https://pith.science/paper/JU7PTNRM}},
  note         = {Machine review of arXiv:2506.15761}
}
read the original abstract

We studied a generalized question: chronic diseases like ME/CFS and long COVID exhibit high heterogeneity with multifactorial etiology and progression, complicating diagnosis and treatment. To address this, we developed BioMapAI, an explainable Deep Learning framework using the richest longitudinal multi-omics dataset for ME/CFS to date. This dataset includes gut metagenomics, plasma metabolome, immune profiling, blood labs, and clinical symptoms. By connecting multi-omics to a symptom matrix, BioMapAI identified both disease- and symptom-specific biomarkers, reconstructed symptoms, and achieved state-of-the-art precision in disease classification. We also created the first connectivity map of these omics in both healthy and disease states and revealed how microbiome-immune-metabolome crosstalk shifted from healthy to ME/CFS.

Figures

Figures reproduced from arXiv: 2506.15761 by the authors.

Figure 1
Figure 1. Summary of study design and analytical pipeline. [PITH_FULL_IMAGE:figures/full_fig_p024_1.png] view at source ↗
Figure 2
Figure 2. Microbial dysbiosis in ME/CFS is characterized by decreased diversity [PITH_FULL_IMAGE:figures/full_fig_p025_2.png] view at source ↗
Figure 3
Figure 3. Significant microbial dysbiosis in observed in short [PITH_FULL_IMAGE:figures/full_fig_p027_3.png] view at source ↗
Figures from the paper (13 more)
Figure 4
Figure 4. Figure 4: Out-performing multi-‘omics model identifies microbial, metagenomic, and metabolic biomarkers for ME/CFS compared to controls. A) Biomarkers from three supervised Gradient Boosting (GDBT) models are shown. Models from top to bottom: species relative abundance, relative…
Figure 5
Figure 5. Figure 5: Phenotypical and metabolic abnormality are most pronounced in long [PITH_FULL_IMAGE:figures/full_fig_p031_5.png]
Figure 6
Figure 6. Figure 6: Limited microbial butyrate biosynthesis capacity associates with [PITH_FULL_IMAGE:figures/full_fig_p033_6.png]
Figure 7
Figure 7. Figure 7: Microbial and metabolomic features of ME/CFS identified in additional [PITH_FULL_IMAGE:figures/full_fig_p035_7.png]
Figure 4
Figure 4. Figure 4: Supplementary [PITH_FULL_IMAGE:figures/full_fig_p056_4.png]
Figure 1
Figure 1. Figure 1: Cohort Summary and Heterogeneity of ME/CFS. A) Cohort Design and [PITH_FULL_IMAGE:figures/full_fig_p069_1.png]
Figure 2
Figure 2. Figure 2: BioMapAI’s Model Structure and Performance. A) Structure of [PITH_FULL_IMAGE:figures/full_fig_p070_2.png]
Figure 3
Figure 3. Figure 3: BioMapAI Identifies both Disease- and Symptom-Specific Biomarkers. For Symptom-Specific Biomarkers, A) Circularized Diagram of Species Model with B) Zoomed Segment for Pain. Each circular panel illustrates how the model predicts each of the 12 symptom-specific biomarke…
Figure 5
Figure 5. Figure 5: Overview of Dysbiotic Host-Microbiome Interactions in ME/CFS. This conceptual diagram visualizes the host-microbiome interactions in healthy conditions (left) and its disruption and transition into the disease state in ME/CFS (right). The base icons of the figure remai…
Figure 2
Figure 2. Figure 2 [PITH_FULL_IMAGE:figures/full_fig_p102_2.png]
Figure 3
Figure 3. Figure 3 [PITH_FULL_IMAGE:figures/full_fig_p104_3.png]
Figure 3
Figure 3. Figure 3: B, which shows the zoomed segment for pain in the species and immune models. Abbreviations and Supporting Materials: Supplemental [PITH_FULL_IMAGE:figures/full_fig_p106_3.png]
Figure 3
Figure 3. Figure 3 [PITH_FULL_IMAGE:figures/full_fig_p108_3.png]

Discussion (0). Continue with ORCID to comment.

Reference graph

Works this paper leans on

202 extracted references · 73 canonical work pages

  1. [1]

    & Buchwald, D

    Afari, N. & Buchwald, D. Chronic fatigue syndrome: a review. Am. J. Psychiatry 160, 221–236 (2003)

    2003

  2. [2]

    Nacul, L. et al. How Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) Progresses: The Natural History of ME/CFS. Front. Neurol. 11, 826 (2020)

    2020

  3. [3]

    T., Komaroff, A

    Holgate, S. T., Komaroff, A. L., Mangan, D. & Wessely, S. Chronic fatigue syndrome: understanding a complex illness. Nat. Rev. Neurosci. 12, 539–544 (2011)

    2011

  4. [4]

    Bested, A. C. & Marshall, L. M. Review of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: an evidence-based approach to diagnosis and management by clinicians. Rev. Environ. Health 30, 223–249 (2015)

    2015

  5. [5]

    Pheby, D. F. H. et al. A Literature Review of GP Knowledge and Understanding of ME/CFS: A Report from the Socioeconomic Working Group of the European Network on ME/CFS (EUROMENE). Medicina (Mex.) 57, 7 (2021)

    2021

  6. [6]

    Naviaux, R. K. et al. Metabolic features of chronic fatigue syndrome. Proc. Natl. Acad. Sci. 113, E5472–E5480 (2016)

    2016

  7. [7]

    & Carding, S

    Navaneetharaja, N., Griffiths, V., Wileman, T. & Carding, S. R. A Role for the Intestinal Microbiota and Virome in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)? J. Clin. Med. 5, E55 (2016)

    2016

  8. [8]

    Sheedy, J. R. et al. Increased d-lactic Acid intestinal bacteria in patients with chronic fatigue syndrome. Vivo Athens Greece 23, 621–628 (2009). 117

    2009

Show all 202 references
  1. [9]

    & De Meirleir, K

    Frémont, M., Coomans, D., Massart, S. & De Meirleir, K. High-throughput 16S rRNA gene sequencing reveals alterations of intestinal microbiota in myalgic encephalomyelitis/chronic fatigue syndrome patients. Anaerobe 22, 50–56 (2013)

    2013

  2. [10]

    Shukla, S. K. et al. Changes in Gut and Plasma Microbiome following Exercise Challenge in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). PloS One 10, e0145453 (2015)

    2015

  3. [11]

    Giloteaux, L. et al. Reduced diversity and altered composition of the gut microbiome in individuals with myalgic encephalomyelitis/chronic fatigue syndrome. Microbiome 4, 30 (2016)

    2016

  4. [12]

    Giloteaux, L., Hanson, M. R. & Keller, B. A. A Pair of Identical Twins Discordant for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Differ in Physiological Parameters and Gut Microbiome Composition. Am. J. Case Rep. 17, 720–729 (2016)

    2016

  5. [13]

    Nagy-Szakal, D. et al. Fecal metagenomic profiles in subgroups of patients with myalgic encephalomyelitis/chronic fatigue syndrome. Microbiome 5, 44 (2017)

    2017

  6. [14]

    Visconti, A. et al. Interplay between the human gut microbiome and host metabolism. Nat. Commun. 10, 4505 (2019)

    2019

  7. [15]

    Wikoff, W. R. et al. Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites. Proc. Natl. Acad. Sci. 106, 3698–3703 (2009)

    2009

  8. [16]

    Turnbaugh, P. J. et al. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 444, 1027–1031 (2006)

    2006

  9. [17]

    V., Littman, D

    Hooper, L. V., Littman, D. R. & Macpherson, A. J. Interactions Between the Microbiota and the Immune System. Science 336, 1268–1273 (2012). 118

    2012

  10. [18]

    Nicholson, J. K. et al. Host-gut microbiota metabolic interactions. Science 336, 1262– 1267 (2012)

    2012

  11. [19]

    M., Walter, J., Segal, E

    Valdes, A. M., Walter, J., Segal, E. & Spector, T. D. Role of the gut microbiota in nutrition and health. BMJ 361, k2179 (2018)

    2018

  12. [20]

    L., Vieira, A., Sato, F

    Corrêa-Oliveira, R., Fachi, J. L., Vieira, A., Sato, F. T. & Vinolo, M. A. R. Regulation of immune cell function by short-chain fatty acids. Clin. Transl. Immunol. 5, e73 (2016)

    2016

  13. [21]

    & Distrutti, E

    Fiorucci, S., Biagioli, M., Zampella, A. & Distrutti, E. Bile Acids Activated Receptors Regulate Innate Immunity. Front. Immunol. 9, 1853 (2018)

    2018

  14. [22]

    Sorgdrager, F. J. H., Naudé, P. J. W., Kema, I. P., Nollen, E. A. & Deyn, P. P. D. Tryptophan Metabolism in Inflammaging: From Biomarker to Therapeutic Target. Front. Immunol. 10, 2565 (2019)

    2019

  15. [23]

    Bellono, N. W. et al. Enterochromaffin Cells Are Gut Chemosensors that Couple to Sensory Neural Pathways. Cell 170, 185-198.e16 (2017)

    2017

  16. [24]

    Bian, X. et al. The artificial sweetener acesulfame potassium affects the gut microbiome and body weight gain in CD-1 mice. PLOS ONE 12, e0178426 (2017)

    2017

  17. [26]

    S., Kumar, S., Mohanty, A

    Singh, K. S., Kumar, S., Mohanty, A. K., Grover, S. & Kaushik, J. K. Mechanistic insights into the host-microbe interaction and pathogen exclusion mediated by the Mucus- binding protein of Lactobacillus plantarum. Sci. Rep. 8, 14198 (2018). 119

    2018

  18. [27]

    Xu, L., Sun, L., Zhang, S., Wang, S. & Lu, M. High-Resolution Profiling of Gut Bacterial Communities in an Invasive Beetle using PacBio SMRT Sequencing System. Insects 10, E248 (2019)

    2019

  19. [28]

    P., Eng, A

    Noecker, C., McNally, C. P., Eng, A. & Borenstein, E. High-Resolution Characterization of the Human Microbiome. Transl. Res. J. Lab. Clin. Med. 179, 7–23 (2017)

    2017

  20. [29]

    McHardy, I. H. et al. Integrative analysis of the microbiome and metabolome of the human intestinal mucosal surface reveals exquisite inter-relationships. Microbiome 1, 17 (2013)

    2013

  21. [30]

    H., Tung, M

    de Mel, S., Lim, S. H., Tung, M. L. & Chng, W.-J. Implications of Heterogeneity in Multiple Myeloma. BioMed Res. Int. 2014, 232546 (2014)

    2014

  22. [31]

    Wallstrom, G., Anderson, K. S. & LaBaer, J. Biomarker Discovery for Heterogeneous Diseases

  23. [32]

    M., McCarthy, T

    Weyand, C. M., McCarthy, T. G. & Goronzy, J. J. Correlation between disease phenotype and genetic heterogeneity in rheumatoid arthritis. J. Clin. Invest. 95, 2120–2126 (1995)

    1995

  24. [33]

    Xiong, R. et al. Multi-‘omics of gut microbiome-host interactions in short- and long- term myalgic encephalomyelitis/chronic fatigue syndrome patients. Cell Host Microbe 31, 273-287.e5 (2023)

    2023

  25. [34]

    & Orr-Urtreger, A

    Giladi, N., Mirelman, A., Thaler, A. & Orr-Urtreger, A. A Personalized Approach to Parkinson’s Disease Patients Based on Founder Mutation Analysis. Front. Neurol. 7, (2016). 120

    2016

  26. [35]

    Brown, S. M. et al. Consistent Effects of Early Remdesivir on Symptoms and Disease Progression Across At-Risk Outpatient Subgroups: Treatment Effect Heterogeneity in PINETREE Study. Infect. Dis. Ther. 12, 1189–1203 (2023)

    2023

  27. [36]

    & Sano, H

    Iwasaki, T. & Sano, H. Predicting Treatment Responses and Disease Progression in Myeloma using Serum Vascular Endothelial Growth Factor and Hepatocyte Growth Factor Levels. Leuk. Lymphoma 44, 1275–1279 (2003)

    2003

  28. [37]

    J., LaGree, T

    Hare, P. J., LaGree, T. J., Byrd, B. A., DeMarco, A. M. & Mok, W. W. K. Single-Cell Technologies to Study Phenotypic Heterogeneity and Bacterial Persisters. Microorganisms 9, 2277 (2021)

    2021

  29. [38]

    M., Haggerty, S

    Cohen, R. M., Haggerty, S. & Herman, W. H. HbA1c for the Diagnosis of Diabetes and Prediabetes: Is It Time for a Mid-Course Correction? J. Clin. Endocrinol. Metab. 95, 5203–5206 (2010)

    2010

  30. [39]

    Zhou, W. et al. Longitudinal multi-omics of host–microbe dynamics in prediabetes. Nature 569, 663–671 (2019)

    2019

  31. [40]

    Hong, S. et al. Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2017. Cancer Res. Treat. 52, 335–350 (2020)

    2020

  32. [41]

    Zeeshan, S., Xiong, R., Liang, B. T. & Ahmed, Z. 100 years of evolving gene–disease complexities and scientific debutants. Brief. Bioinform. 21, 885–905 (2020)

    2020

  33. [42]

    T., Arcos-Burgos, M

    Cortes Rivera, M., Mastronardi, C., Silva-Aldana, C. T., Arcos-Burgos, M. & Lidbury, B. A. Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Comprehensive Review. Diagnostics 9, 91 (2019). 121

    2019

  34. [43]

    Sweetman, E. et al. Current Research Provides Insight into the Biological Basis and Diagnostic Potential for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). Diagnostics 9, 73 (2019)

    2019

  35. [44]

    Noor, N. et al. A Comprehensive Update of the Current Understanding of Chronic Fatigue Syndrome. Anesthesiol. Pain Med. 11, e113629 (2021)

    2021

  36. [45]

    & Zabaleta, A

    Ruiz-Pablos, M., Paiva, B., Montero-Mateo, R., Garcia, N. & Zabaleta, A. Epstein-Barr Virus and the Origin of Myalgic Encephalomyelitis or Chronic Fatigue Syndrome. Front. Immunol. 12, 656797 (2021)

    2021

  37. [46]

    Su, R. et al. The TLR3/IRF1/Type III IFN Axis Facilitates Antiviral Responses against Enterovirus Infections in the Intestine. mBio 11, 10.1128/mbio.02540-20 (2020)

    2020 doi

  38. [47]

    Anderson, D. E. et al. Lack of cross-neutralization by SARS patient sera towards SARS- CoV-2. Emerg. Microbes Infect. 9, 900–902 (2020)

    2020

  39. [48]

    J., Corrales-Medina, V

    Poenaru, S., Abdallah, S. J., Corrales-Medina, V. & Cowan, J. COVID-19 and post- infectious myalgic encephalomyelitis/chronic fatigue syndrome: a narrative review. Ther. Adv. Infect. Dis. 8, 20499361211009385 (2021)

    2021

  40. [49]

    Reuken, P. A. et al. Longterm course of neuropsychological symptoms and ME/CFS after SARS-CoV-2-infection: a prospective registry study. Eur. Arch. Psychiatry Clin. Neurosci. (2023) doi:10.1007/s00406-023-01661-3

    2023 doi

  41. [50]

    Lim, E.-J. et al. Systematic review and meta-analysis of the prevalence of chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME). J. Transl. Med. 18, 100 (2020). 122

    2020

  42. [51]

    Shikova, E. et al. Cytomegalovirus, Epstein-Barr virus, and human herpesvirus-6 infections in patients with myalgic еncephalomyelitis/chronic fatigue syndrome. J. Med. Virol. (2020) doi:10.1002/jmv.25744

    2020 doi

  43. [52]

    Clmc, van C., Fwa, V., Pc, R. & Fc, V. Cerebral blood flow is reduced in ME/CFS during head-up tilt testing even in the absence of hypotension or tachycardia: A quantitative, controlled study using Doppler echography. Clin. Neurophysiol. Pract. 5, (2020)

    2020

  44. [53]

    & De Meirleir, K

    De Becker, P., McGregor, N. & De Meirleir, K. A definition-based analysis of symptoms in a large cohort of patients with chronic fatigue syndrome. J. Intern. Med. 250, 234– 240 (2001)

    2001

  45. [54]

    Roma, M. et al. Impaired Health-Related Quality of Life in Adolescent Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: The Impact of Core Symptoms. Front. Pediatr. 7, 26 (2019)

    2019

  46. [55]

    J., Oh, J., Robison, J., Grady, J

    Larson, P. J., Oh, J., Robison, J., Grady, J. & Kuchel, G. 1206. Association of Aging, Frailty and Place of Residence with Skin, Oral and Gut Microbiome Characteristics and Pathogenicity Reservoirs. Open Forum Infect. Dis. 7, S625 (2020)

    2020

  47. [56]

    Larson, P. J. et al. Associations of the skin, oral and gut microbiome with aging, frailty and infection risk reservoirs in older adults. Nat. Aging 2, 941–955 (2022)

    2022

  48. [57]

    & Hugot, J

    Mosca, A., Leclerc, M. & Hugot, J. P. Gut Microbiota Diversity and Human Diseases: Should We Reintroduce Key Predators in Our Ecosystem? Front. Microbiol. 7, 455 (2016)

    2016

  49. [58]

    A biodiversity hypothesis

    Haahtela, T. A biodiversity hypothesis. Allergy 74, 1445–1456 (2019). 123

    2019

  50. [59]

    Behary, J. et al. Gut microbiota impact on the peripheral immune response in non- alcoholic fatty liver disease related hepatocellular carcinoma. Nat. Commun. 12, 187 (2021)

    2021

  51. [60]

    M., Sun, E

    Martin, A. M., Sun, E. W., Rogers, G. B. & Keating, D. J. The Influence of the Gut Microbiome on Host Metabolism Through the Regulation of Gut Hormone Release. Front. Physiol. 10, 428 (2019)

    2019

  52. [61]

    Muñiz Pedrogo, D. A. et al. An Increased Abundance of Clostridiaceae Characterizes Arthritis in Inflammatory Bowel Disease and Rheumatoid Arthritis: A Cross-sectional Study. Inflamm. Bowel Dis. 25, 902–913 (2019)

    2019

  53. [62]

    Emiola, A. & Oh, J. High throughput in situ metagenomic measurement of bacterial replication at ultra-low sequencing coverage. Nat. Commun. 9, 4956 (2018)

    2018

  54. [63]

    Canani, R. B. et al. Potential beneficial effects of butyrate in intestinal and extraintestinal diseases. World J. Gastroenterol. WJG 17, 1519–1528 (2011)

    2011

  55. [64]

    Ferrer-Picón, E. et al. Intestinal Inflammation Modulates the Epithelial Response to Butyrate in Patients With Inflammatory Bowel Disease. Inflamm. Bowel Dis. 26, 43–55 (2020)

    2020

  56. [65]

    & Van de Wiele, T

    Hosseini, E., Grootaert, C., Verstraete, W. & Van de Wiele, T. Propionate as a health- promoting microbial metabolite in the human gut. Nutr. Rev. 69, 245–258 (2011)

    2011

  57. [66]

    Tryptophan Dietary Impacts Gut Barrier and Metabolic Diseases

    Taleb, S. Tryptophan Dietary Impacts Gut Barrier and Metabolic Diseases. Front. Immunol. 10, 2113 (2019)

    2019

  58. [67]

    K., Jung, K

    Go, E. K., Jung, K. J., Kim, J. Y., Yu, B. P. & Chung, H. Y. Betaine Suppresses Proinflammatory Signaling During Aging: The Involvement of Nuclear Factor-κB via 124 Nuclear Factor-Inducing Kinase/IκB Kinase and Mitogen-Activated Protein Kinases. J. Gerontol. Ser. A 60, 1252–12...

    2005

  59. [68]

    Zhao, G. et al. Betaine in Inflammation: Mechanistic Aspects and Applications. Front. Immunol. 9, 1070 (2018)

    2018

  60. [70]

    Nkiliza, A. et al. Sex-specific plasma lipid profiles of ME/CFS patients and their association with pain, fatigue, and cognitive symptoms. J. Transl. Med. 19, 370 (2021)

    2021

  61. [71]

    Noda, M., Ifuku, M., Hossain, Md. S. & Katafuchi, T. Glial Activation and Expression of the Serotonin Transporter in Chronic Fatigue Syndrome. Front. Psychiatry 9, 589 (2018)

    2018

  62. [72]

    Guo, P., Zhang, K., Ma, X. & He, P. Clostridium species as probiotics: potentials and challenges. J. Anim. Sci. Biotechnol. 11, 24 (2020)

    2020

  63. [73]

    Brkic, S., Tomic, S., Maric, D., Mikic, A. N. & Turkulov, V. Lipid peroxidation is elevated in female patients with chronic fatigue syndrome. Med. Sci. Monit. 16, CR628–CR632 (2010)

    2010

  64. [74]

    & Mikic, A

    Tomic, S., Brkic, S., Maric, D. & Mikic, A. N. Lipid and protein oxidation in female patients with chronic fatigue syndrome. Arch. Med. Sci. AMS 8, 886–891 (2012)

    2012

  65. [75]

    Low T3 Syndrome

    Ruiz-Núñez, B., Tarasse, R., Vogelaar, E. F., Janneke Dijck-Brouwer, D. A. & Muskiet, F. A. J. Higher Prevalence of “Low T3 Syndrome” in Patients With Chronic Fatigue Syndrome: A Case–Control Study. Front. Endocrinol. 9, 97 (2018). 125

    2018

  66. [76]

    & Evans, M

    Flores, S., Brown, A., Adeoye, S., Jason, L. & Evans, M. Examining the Impact of Obesity on Individuals with CFS. Workplace Health Saf. 61, 299–307 (2013)

    2013

  67. [77]

    Germain, A., Ruppert, D., Levine, S. M. & Hanson, M. R. Prospective Biomarkers from Plasma Metabolomics of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Implicate Redox Imbalance in Disease Symptomatology. Metabolites 8, 90 (2018)

    2018

  68. [78]

    Lakhan, S. E. & Kirchgessner, A. Gut inflammation in chronic fatigue syndrome. Nutr. Metab. 7, 79 (2010)

    2010

  69. [79]

    Jackson, M. L. & Bruck, D. Sleep Abnormalities in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis: A Review. J. Clin. Sleep Med. JCSM Off. Publ. Am. Acad. Sleep Med. 8, 719–728 (2012)

    2012

  70. [80]

    Boneva, R. S. et al. Endometriosis as a Comorbid Condition in Chronic Fatigue Syndrome (CFS): Secondary Analysis of Data From a CFS Case-Control Study. Front. Pediatr. 7, 195 (2019)

    2019

  71. [81]

    W., Young, W

    Pataky, M. W., Young, W. F. & Nair, K. S. Hormonal and Metabolic Changes of Aging and the Influence of Lifestyle Modifications. Mayo Clin. Proc. 96, 788–814 (2021)

    2021

  72. [82]

    & Kozak, Leslie

    Jura, M. & Kozak, Leslie. P. Obesity and related consequences to ageing. Age 38, 23 (2016)

    2016

  73. [83]

    Natelson, B. H. Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and Fibromyalgia: Definitions, Similarities and Differences. Clin. Ther. 41, 612–618 (2019)

    2019

  74. [84]

    Harris, S. et al. A qualitative investigation of eating difficulties in adolescents with chronic fatigue syndrome/myalgic encephalomyelitis. Clin. Child Psychol. Psychiatry 22, 128–139 (2017). 126

    2017

  75. [85]

    Donohoe, D. R. et al. The Microbiome and Butyrate Regulate Energy Metabolism and Autophagy in the Mammalian Colon. Cell Metab. 13, 517–526 (2011)

    2011

  76. [86]

    Müller, M. et al. Circulating but not faecal short-chain fatty acids are related to insulin sensitivity, lipolysis and GLP-1 concentrations in humans. Sci. Rep. 9, 12515 (2019)

    2019

  77. [87]

    Guo, C. et al. Deficient butyrate-producing capacity in the gut microbiome of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome patients is associated with fatigue symptoms. 2021.10.27.21265575 Preprint at https://doi.org/10.1101/2021.10.27.21265575 (2021)

    2021 doi

  78. [88]

    & Marshall, T

    Proal, A. & Marshall, T. Myalgic Encephalomyelitis/Chronic Fatigue Syndrome in the Era of the Human Microbiome: Persistent Pathogens Drive Chronic Symptoms by Interfering With Host Metabolism, Gene Expression, and Immunity. Front. Pediatr. 6, 373 (2018)

    2018

  79. [89]

    Lupo, G. F. D. et al. Potential role of microbiome in Chronic Fatigue Syndrome/Myalgic Encephalomyelits (CFS/ME). Sci. Rep. 11, 7043 (2021)

    2021

  80. [90]

    Sanchez-Morate, E. et al. Relationship between Diet, Microbiota, and Healthy Aging. Biomedicines 8, 287 (2020)

    2020

  81. [91]

    Fromentin, S. et al. Microbiome and metabolome features of the cardiometabolic disease spectrum. Nat. Med. 28, 303–314 (2022)

    2022

  82. [92]

    Karhan, E. et al. Perturbation of Effector and Regulatory T Cell Subsets in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). 2019.12.23.887505 https://www.biorxiv.org/content/10.1101/2019.12.23.887505v1 (2019) doi:10.1101/2019.12.23.887505. 127

    2019 doi

  83. [93]

    Russell, L. et al. Illness progression in chronic fatigue syndrome: a shifting immune baseline. BMC Immunol. 17, 3 (2016)

    2016

  84. [94]

    Bar, N. et al. A reference map of potential determinants for the human serum metabolome. Nature 588, 135–140 (2020)

    2020

  85. [95]

    Yancey, J. R. & Thomas, S. M. Chronic fatigue syndrome: diagnosis and treatment. Am. Fam. Physician 86, 741–746 (2012)

    2012

  86. [96]

    Hickie, I. et al. Post-infective and chronic fatigue syndromes precipitated by viral and non-viral pathogens: prospective cohort study. BMJ 333, 575 (2006)

    2006

  87. [97]

    Pendergrast, T. et al. Housebound versus nonhousebound patients with myalgic encephalomyelitis and chronic fatigue syndrome. Chronic Illn. 12, 292–307 (2016)

    2016

  88. [98]

    Komaroff, A. L. & Bateman, L. Will COVID-19 Lead to Myalgic Encephalomyelitis/Chronic Fatigue Syndrome? Front. Med. 7, 1132 (2021)

    2021

  89. [99]

    Fukuda, K. et al. The chronic fatigue syndrome: a comprehensive approach to its definition and study. International Chronic Fatigue Syndrome Study Group. Ann. Intern. Med. 121, 953–959 (1994)

    1994

  90. [100]

    Carruthers, B. M. Definitions and aetiology of myalgic encephalomyelitis: how the Canadian consensus clinical definition of myalgic encephalomyelitis works. J. Clin. Pathol. 60, 117–119 (2007)

    2007

  91. [101]

    Beyond Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Redefining an Illness

    Committee on the Diagnostic Criteria for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome, Board on the Health of Select Populations, & Institute of Medicine. Beyond Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Redefining an Illness. (National Academies Press (US), Wa...

    2015

  92. [102]

    Beghini, F. et al. Integrating taxonomic, functional, and strain-level profiling of diverse microbial communities with bioBakery 3. eLife 10, e65088 (2021)

    2021

  93. [104]

    I., Huber, W

    Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014)

    2014

  94. [105]

    R., van Verk, M

    Garza, D. R., van Verk, M. C., Huynen, M. A. & Dutilh, B. E. Towards predicting the environmental metabolome from metagenomics with a mechanistic model. Nat. Microbiol. 3, 456–460 (2018)

    2018

  95. [106]

    Mallick, H. et al. Multivariable association discovery in population-scale meta-omics studies. PLoS Comput. Biol. 17, e1009442 (2021)

    2021

  96. [107]

    Bretherick, A. D. et al. Typing myalgic encephalomyelitis by infection at onset: A DecodeME study. NIHR Open Res. 3, 20 (2023)

    2023

  97. [108]

    & Lin, J.-M

    Bae, J. & Lin, J.-M. S. Healthcare Utilization in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): Analysis of US Ambulatory Healthcare Data, 2000–2009. Front. Pediatr. 7, (2019)

    2019

  98. [109]

    & Zhu, Z

    Zheng, Y. & Zhu, Z. Editorial: Retrieving meaningful patterns from big biomedical data with machine learning approaches. Front. Genet. 14, (2023)

    2023

  99. [110]

    Leelatian, N. et al. Unsupervised machine learning reveals risk stratifying glioblastoma tumor cells. eLife 9, e56879 (2020)

    2020

  100. [111]

    Su, Q. et al. The gut microbiome associates with phenotypic manifestations of post- acute COVID-19 syndrome. Cell Host Microbe 32, 651-660.e4 (2024). 129

    2024

  101. [112]

    R., van Goor, H., Faber, K

    Bourgonje, A. R., van Goor, H., Faber, K. N. & Dijkstra, G. Clinical Value of Multiomics- Based Biomarker Signatures in Inflammatory Bowel Diseases: Challenges and Opportunities. Clin. Transl. Gastroenterol. 14, e00579 (2023)

    2023

  102. [113]

    Marcos-Zambrano, L. J. et al. Applications of Machine Learning in Human Microbiome Studies: A Review on Feature Selection, Biomarker Identification, Disease Prediction and Treatment. Front. Microbiol. 12, (2021)

    2021

  103. [114]

    Guo, C. et al. Deficient butyrate-producing capacity in the gut microbiome is associated with bacterial network disturbances and fatigue symptoms in ME/CFS. Cell Host Microbe 31, 288-304.e8 (2023)

    2023

  104. [115]

    Raijmakers, R. P. H. et al. Multi-omics examination of Q fever fatigue syndrome identifies similarities with chronic fatigue syndrome. J. Transl. Med. 18, 448 (2020)

    2020

  105. [116]

    Germain, A. et al. Plasma metabolomics reveals disrupted response and recovery following maximal exercise in myalgic encephalomyelitis/chronic fatigue syndrome. JCI Insight 7, (2023)

    2023

  106. [117]

    Che, X. et al. Metabolomic Evidence for Peroxisomal Dysfunction in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. Int. J. Mol. Sci. 23, 7906 (2022)

    2022

  107. [118]

    Liñares-Blanco, J., Fernandez-Lozano, C., Seoane, J. A. & López-Campos, G. Machine Learning Based Microbiome Signature to Predict Inflammatory Bowel Disease Subtypes. Front. Microbiol. 13, (2022)

    2022

  108. [119]

    He, F. et al. Development and External Validation of Machine Learning Models for Diabetic Microvascular Complications: Cross-Sectional Study With Metabolites. J. Med. Internet Res. 26, e41065 (2024). 130

    2024

  109. [120]

    Hawken, S. et al. External validation of machine learning models including newborn metabolomic markers for postnatal gestational age estimation in East and South-East Asian infants. Preprint at https://doi.org/10.12688/gatesopenres.13131.2 (2021)

    2021 doi

  110. [121]

    & Claus, S

    Mora-Ortiz, M., Trichard, M., Oregioni, A. & Claus, S. P. Thanatometabolomics: introducing NMR-based metabolomics to identify metabolic biomarkers of the time of death. Metabolomics 15, 37 (2019)

    2019

  111. [122]

    Balasubramanian, R. et al. Metabolomic profiles associated with all-cause mortality in the Women’s Health Initiative. Int. J. Epidemiol. 49, 289–300 (2020)

    2020

  112. [123]

    Li, H., Ren, M. & Li, Q. 1H NMR-Based Metabolomics Reveals the Intrinsic Interaction of Age, Plasma Signature Metabolites, and Nutrient Intake in the Longevity Population in Guangxi, China. Nutrients 14, 2539 (2022)

    2022

  113. [124]

    & Kameda, M

    Kondoh, H. & Kameda, M. Metabolites in aging and aging-relevant diseases: Frailty, sarcopenia and cognitive decline. Geriatr. Gerontol. Int. 24, 44–48 (2024)

    2024

  114. [125]

    & Zhang, J

    Peng, S., Shen, Y., Wang, M. & Zhang, J. Serum and CSF Metabolites in Stroke-Free Patients Are Associated With Vascular Risk Factors and Cognitive Performance. Front. Aging Neurosci. 12, (2020)

    2020

  115. [126]

    Duerler, P., Vollenweider, F. X. & Preller, K. H. A neurobiological perspective on social influence: Serotonin and social adaptation. J. Neurochem. 162, 60–79 (2022)

    2022

  116. [127]

    B., Paliarin, F

    Pomrenze, M. B., Paliarin, F. & Maiya, R. Friend of the Devil: Negative Social Influences Driving Substance Use Disorders. Front. Behav. Neurosci. 16, (2022). 131

    2022

  117. [128]

    Commentary on Bischof et al.: Empirical and conceptual paradigms for studying secondary impacts of a person’s substance use

    Laslett, A.-M. Commentary on Bischof et al.: Empirical and conceptual paradigms for studying secondary impacts of a person’s substance use. Addiction 117, 3148–3149 (2022)

    2022

  118. [129]

    Carco, C. et al. Increasing Evidence That Irritable Bowel Syndrome and Functional Gastrointestinal Disorders Have a Microbial Pathogenesis. Front. Cell. Infect. Microbiol. 10, (2020)

    2020

  119. [130]

    Saffouri, G. B. et al. Small intestinal microbial dysbiosis underlies symptoms associated with functional gastrointestinal disorders. Nat. Commun. 10, 2012 (2019)

    2019

  120. [131]

    & Jin, F

    Liang, S., Wu, X., Hu, X., Wang, T. & Jin, F. Recognizing Depression from the Microbiota–Gut–Brain Axis. Int. J. Mol. Sci. 19, 1592 (2018)

    2018

  121. [132]

    & Chen, T

    Zhu, F., Tu, H. & Chen, T. The Microbiota–Gut–Brain Axis in Depression: The Potential Pathophysiological Mechanisms and Microbiota Combined Antidepression Effect. Nutrients 14, 2081 (2022)

    2022

  122. [133]

    & Scott, S

    Topan, R. & Scott, S. M. Sleep: An Overlooked Lifestyle Factor in Disorders of Gut- Brain Interaction. Curr. Treat. Options Gastroenterol. 21, 435–446 (2023)

    2023

  123. [134]

    Moens de Hase, E. et al. Impact of metformin and Dysosmobacter welbionis on diet- induced obesity and diabetes: from clinical observation to preclinical intervention. Diabetologia 67, 333–345 (2024)

    2024

  124. [135]

    O., Agbalalah, T

    Amabebe, E., Robert, F. O., Agbalalah, T. & Orubu, E. S. F. Microbial dysbiosis- induced obesity: role of gut microbiota in homoeostasis of energy metabolism. Br. J. Nutr. 123, 1127–1137 (2020). 132

    2020

  125. [136]

    Kavanagh, P. et al. Tentative identification of the phase I and II metabolites of two synthetic cathinones, MDPHP and α-PBP, in human urine. Drug Test. Anal. 12, 1442– 1451 (2020)

    2020

  126. [137]

    Wang, J.-H. et al. Clinical evidence of the link between gut microbiome and myalgic encephalomyelitis/chronic fatigue syndrome: a retrospective review. Eur. J. Med. Res. 29, 148 (2024)

    2024

  127. [138]

    Lenoir, M. et al. Butyrate mediates anti-inflammatory effects of Faecalibacterium prausnitzii in intestinal epithelial cells through Dact3. Gut Microbes (2020)

    2020

  128. [139]

    Sokol, H. et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc. Natl. Acad. Sci. 105, 16731–16736 (2008)

    2008

  129. [140]

    Quévrain, E. et al. Identification of an anti-inflammatory protein from Faecalibacterium prausnitzii, a commensal bacterium deficient in Crohn’s disease. Gut 65, 415–425 (2016)

    2016

  130. [141]

    Miquel, S. et al. Identification of Metabolic Signatures Linked to Anti-Inflammatory Effects of Faecalibacterium prausnitzii. mBio 6, 10.1128/mbio.00300-15 (2015)

    2015 doi

  131. [142]

    Vital, M., Howe, A. C. & Tiedje, J. M. Revealing the Bacterial Butyrate Synthesis Pathways by Analyzing (Meta)genomic Data. mBio 5, e00889-14 (2021)

    2021

  132. [143]

    & Shi, X.-Z

    Recharla, N., Geesala, R. & Shi, X.-Z. Gut Microbial Metabolite Butyrate and Its Therapeutic Role in Inflammatory Bowel Disease: A Literature Review. Nutrients 15, 2275 (2023). 133

    2023

  133. [144]

    Monteiro, C. R. A. V. et al. In Vitro Antimicrobial Activity and Probiotic Potential of Bifidobacterium and Lactobacillus against Species of Clostridium. Nutrients 11, 448 (2019)

    2019

  134. [145]

    & Deng, Y

    Zhao, M., Li, G. & Deng, Y. Engineering Escherichia coli for Glutarate Production as the C5 Platform Backbone. Appl. Environ. Microbiol. 84, e00814-18 (2018)

    2018

  135. [146]

    T., Selzner, N., Wrana, J

    Nguyen-Lefebvre, A. T., Selzner, N., Wrana, J. L. & Bhat, M. The hippo pathway: A master regulator of liver metabolism, regeneration, and disease. FASEB J. 35, e21570 (2021)

    2021

  136. [147]

    A., Gupta, A., Sastry, J

    Khan, M. A., Gupta, A., Sastry, J. L. N. & Ahmad, S. Hepatoprotective potential of kumaryasava and its concentrate against CCl4-induced hepatic toxicity in Wistar rats. J. Pharm. Bioallied Sci. 7, 297–299 (2015)

    2015

  137. [148]

    Roles of Diet-Associated Gut Microbial Metabolites on Brain Health: Cell- to-Cell Interactions between Gut Bacteria and the Central Nervous System

    Kim, C.-S. Roles of Diet-Associated Gut Microbial Metabolites on Brain Health: Cell- to-Cell Interactions between Gut Bacteria and the Central Nervous System. Adv. Nutr. 15, 100136 (2024)

    2024

  138. [149]

    & Pot, C

    Rebeaud, J., Peter, B. & Pot, C. How Microbiota-Derived Metabolites Link the Gut to the Brain during Neuroinflammation. Int. J. Mol. Sci. 23, 10128 (2022)

    2022

  139. [150]

    Ahmad, S. et al. Gut microbiome-related metabolites in plasma are associated with general cognition. Alzheimers Dement. 17, e056142 (2021)

    2021

  140. [151]

    L., Bleiberg, J., Vice, J

    Lathan, C., Spira, J. L., Bleiberg, J., Vice, J. & Tsao, J. W. Defense Automated Neurobehavioral Assessment (DANA)-psychometric properties of a new field- deployable neurocognitive assessment tool. Mil. Med. 178, 365–371 (2013). 134

    2013

  141. [152]

    Resnick, H. E. & Lathan, C. E. From battlefield to home: a mobile platform for assessing brain health. mHealth 2, 30 (2016)

    2016

  142. [153]

    Lee, J. et al. Hemodynamics during the 10-minute NASA Lean Test: evidence of circulatory decompensation in a subset of ME/CFS patients. J. Transl. Med. 18, 314 (2020)

    2020

  143. [154]

    Beyond Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Redefining an Illness

    Committee on the Diagnostic Criteria for Myalgic Encephalomyelitis/ChronicFatigue Syndrome, Board on the Health of Select Populations, & Institute of Medicine. Beyond Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Redefining an Illness. (National Academies Press (US), Was...

    2015

  144. [155]

    36-Item Short Form Survey (SF-36) Scoring Instructions

    Monica, 1776 Main Street Santa & California 90401-3208. 36-Item Short Form Survey (SF-36) Scoring Instructions. https://www.rand.org/health- care/surveys_tools/mos/36-item-short-form/scoring.html

  145. [156]

    Shen, W., Le, S., Li, Y. & Hu, F. SeqKit: A Cross-Platform and Ultrafast Toolkit for FASTA/Q File Manipulation. PLOS ONE 11, e0163962 (2016)

    2016

  146. [157]

    Blanco-Míguez, A. et al. Extending and improving metagenomic taxonomic profiling with uncharacterized species using MetaPhlAn 4. Nat. Biotechnol. 41, 1633–1644 (2023)

    2023

  147. [158]

    Edgar, R. C. Search and clustering orders of magnitude faster than BLAST. Bioinformatics 26, 2460–2461 (2010)

    2010

  148. [159]

    I., Huber, W

    Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014). 135

    2014

  149. [160]

    V., Bowyer, K

    Chawla, N. V., Bowyer, K. W., Hall, L. O. & Kegelmeyer, W. P. SMOTE: Synthetic Minority Over-sampling Technique. J. Artif. Intell. Res. 16, 321–357 (2002)

    2002

  150. [161]

    A., & Shutao Li

    Haibo He, Yang Bai, Garcia, E. A., & Shutao Li. ADASYN: Adaptive synthetic sampling approach for imbalanced learning. in 2008 IEEE International Joint Conference on Neural Networks (IEEE World Congress on Computational Intelligence) 1322–1328 (IEEE, Hong Kong, China, 2008). do...

    2008

  151. [162]

    & Jorgensen, B

    Saripuddin, M., Suliman, A., Syarmila Sameon, S. & Jorgensen, B. N. Random Undersampling on Imbalance Time Series Data for Anomaly Detection. in Proceedings of the 2021 4th International Conference on Machine Learning and Machine Intelligence 151–156 (Association for Computing...

    2021

  152. [163]

    & Lee, S.-I

    Lundberg, S. & Lee, S.-I. A Unified Approach to Interpreting Model Predictions. Preprint at https://doi.org/10.48550/arXiv.1705.07874 (2017)

    2017 doi arXiv

  153. [164]

    Abadi, M. et al. TensorFlow: A system for large-scale machine learning. Preprint at https://doi.org/10.48550/arXiv.1605.08695 (2016)

    2016 doi arXiv

  154. [165]

    Pedregosa, F. et al. Scikit-learn: Machine Learning in Python. Preprint at https://doi.org/10.48550/arXiv.1201.0490 (2018)

    2018 doi arXiv

  155. [166]

    & Horvath, S

    Langfelder, P. & Horvath, S. WGCNA: an R package for weighted correlation network analysis. BMC Bioinformatics 9, 559 (2008)

    2008

  156. [167]

    Antonov, M. et al. igraph enables fast and robust network analysis across programming languages. Preprint at https://doi.org/10.48550/arXiv.2311.10260 (2023). 136

    2023 doi arXiv

  157. [168]

    Koo, T. K. & Li, M. Y. A Guideline of Selecting and Reporting Intraclass Correlation Coefficients for Reliability Research. J. Chiropr. Med. 15, 155–163 (2016)

    2016

  158. [169]

    Nelder, J. A. & Wedderburn, R. W. M. Generalized Linear Models. J. R. Stat. Soc. Ser. Gen. 135, 370–384 (1972)

    1972

  159. [170]

    Bakdash, J. Z. & Marusich, L. R. Repeated Measures Correlation. Front. Psychol. 8, (2017)

    2017

  160. [171]

    Smoothing Spline ANOVA Models: R Package gss

    Gu, C. Smoothing Spline ANOVA Models: R Package gss. Smoothing Spline ANOVA Models

  161. [172]

    & Liang, B

    Ahmed, Z., Zeeshan, S., Xiong, R. & Liang, B. T. Debutant iOS app and gene‐disease complexities in clinical genomics and precision medicine. Clin. Transl. Med. 8, e26 (2019)

    2019

  162. [173]

    & Liang, B

    Ahmed, Z., Zeeshan, S., Xiong, R. & Liang, B. T. PAS-Gen: Guide to iOS app with gene- disease

  163. [174]

    & Zhong, W

    Ahmed, Z., Wan, S., Zhang, F. & Zhong, W. Artificial intelligence for omics data analysis. BMC Methods 1, 4 (2024)

    2024

  164. [175]

    & Dong, X

    Ahmed, Z., Mohamed, K., Zeeshan, S. & Dong, X. Artificial intelligence with multi- functional machine learning platform development for better healthcare and precision medicine. Database J. Biol. Databases Curation 2020, baaa010 (2020)

    2020

  165. [176]

    Germain, A., Ruppert, D., Levine, S. M. & Hanson, M. R. Prospective Biomarkers from Plasma Metabolomics of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Implicate Redox Imbalance in Disease Symptomatology. Metabolites 8, 90 (2018). 137

    2018

  166. [177]

    & Son, C.-G

    Lim, E.-J. & Son, C.-G. Review of case definitions for myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). J. Transl. Med. 18, 289 (2020)

    2020

  167. [178]

    K., Levine, S

    Germain, A., Barupal, D. K., Levine, S. M. & Hanson, M. R. Comprehensive Circulatory Metabolomics in ME/CFS Reveals Disrupted Metabolism of Acyl Lipids and Steroids. Metabolites 10, 34 (2020)

    2020

  168. [179]

    Holistic Treatment of Fibromyalgia Based on Physiopathology: An Expert Opinion

    Martínez-Lavín, M. Holistic Treatment of Fibromyalgia Based on Physiopathology: An Expert Opinion. JCR J. Clin. Rheumatol. 26, 204 (2020)

    2020

  169. [180]

    López-Hernández, Y. et al. The plasma metabolome of long COVID patients two years after infection. Sci. Rep. 13, 12420 (2023)

    2023

  170. [181]

    Iqbal, M., Elzembely, H. I. & Said, O. M. Letter to the Editor: &ldquo;Self-Reported Student Awareness and Prevalence of Computer Vision Syndrome During COVID-19 Pandemic at Al-Baha University&rdquo; [Letter]. Clin. Optom. 14, 193–194 (2022)

    2022

  171. [182]

    Sedeh, F. B. et al. The correlation between self‐reported hand eczema and clinically based diagnosis in professional cleaners. Contact Dermatitis cod.14611 (2024) doi:10.1111/cod.14611

    2024 doi

  172. [183]

    A., Yoo, S

    Jason, L. A., Yoo, S. & Bhatia, S. Patient perceptions of infectious illnesses preceding Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. Chronic Illn. 18, 901–910 (2022)

    2022

  173. [184]

    Hanson, M. R. The viral origin of myalgic encephalomyelitis/chronic fatigue syndrome. PLOS Pathog. 19, e1011523 (2023). 138

    2023

  174. [185]

    Hamine, S., Gerth-Guyette, E., Faulx, D., Green, B. B. & Ginsburg, A. S. Impact of mHealth Chronic Disease Management on Treatment Adherence and Patient Outcomes: A Systematic Review. J. Med. Internet Res. 17, e3951 (2015)

    2015

  175. [186]

    Clark, N. M. Management of Chronic Disease by Patients. Annu. Rev. Public Health 24, 289–313 (2003)

    2003

  176. [187]

    Derman, I. D. et al. High-throughput bioprinting of the nasal epithelium using patient- derived nasal epithelial cells. Biofabrication 15, 044103 (2023)

    2023

  177. [188]

    Fleming, E. et al. Cultivation of common bacterial species and strains from human skin, oral, and gut microbiota. BMC Microbiol. 21, 278 (2021)

    2021

  178. [189]

    C., Hlavacek, P

    Ren, J., Cislo, P., Cappelleri, J. C., Hlavacek, P. & DiBonaventura, M. Comparing g- computation, propensity score-based weighting, and targeted maximum likelihood estimation for analyzing externally controlled trials with both measured and unmeasured confounders: a simulation...

    2023

  179. [190]

    V., Buchman, L

    Lynn, J. V., Buchman, L. K., Breuler, C. J. & Buchman, S. R. Surgical Timing and Neurocognitive Development among Patients with Craniosynostosis: Analysis of Confounders. Plast. Reconstr. Surg. 151, 821 (2023)

    2023

  180. [191]

    Krumina, A. et al. Clinical Profile and Aspects of Differential Diagnosis in Patients with ME/CFS from Latvia. Medicina (Mex.) 57, 958 (2021)

    2021

  181. [192]

    Zubcevik, N. et al. Symptom Clusters and Functional Impairment in Individuals Treated for Lyme Borreliosis. Front. Med. 7, (2020). 139

    2020

  182. [193]

    G., Pereira, A

    Costa, G. G., Pereira, A. R. & Carvalho, A. S. Pericardite lúpica: dor torácica e febre em tempos de COVID-19. Rev. Port. Med. Geral E Fam. 38, 300–4 (2022)

    2022

  183. [194]

    & Finlay, A

    Vyas, J., Muirhead, N., Singh, R., Ephgrave, R. & Finlay, A. Y. Impact of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) on the quality of life of people with ME/CFS and their partners and family members: an online cross-sectional survey. BMJ Open 12, e058128 (2022)

    2022

  184. [195]

    & Wells, B

    Martinez, A., Okoh, A., Ko, Y.-A. & Wells, B. Racial Differences in FMD. 2023.02.10.23285630 Preprint at https://doi.org/10.1101/2023.02.10.23285630 (2023)

    2023 doi

  185. [196]

    Trivedi, M. S. et al. Identification of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome-associated DNA methylation patterns. PLOS ONE 13, e0201066 (2018)

    2018

  186. [197]

    Bouquet, J. et al. Whole blood human transcriptome and virome analysis of ME/CFS patients experiencing post-exertional malaise following cardiopulmonary exercise testing. PLOS ONE 14, e0212193 (2019)

    2019

  187. [198]

    Lande, A. et al. Human Leukocyte Antigen alleles associated with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). Sci. Rep. 10, 5267 (2020)

    2020

  188. [199]

    Almenar-Pérez, E. et al. Epigenetic Components of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Uncover Potential Transposable Element Activation. Clin. Ther. 41, 675–698 (2019)

    2019

  189. [200]

    & Gardner, S

    Das, S., Taylor, K., Kozubek, J., Sardell, J. & Gardner, S. Genetic risk factors for ME/CFS identified using combinatorial analysis. J. Transl. Med. 20, 598 (2022). 140

    2022

  190. [201]

    J., Roman, M., Hernández-Sánchez, J

    Caruana, E. J., Roman, M., Hernández-Sánchez, J. & Solli, P. Longitudinal studies. J. Thorac. Dis. 7, E537–E540 (2015)

    2015

  191. [202]

    White, R. T. & Arzi, H. J. Longitudinal Studies: Designs, Validity, Practicality, and Value. Res. Sci. Educ. 35, 137–149 (2005)

    2005

  192. [203]

    & Adina, H

    Aurora, C., Cecilia, A. & Adina, H. The Role of Diet in the Treatment of Chronic Diseases Case Study. ARS Medica Tomitana 27, 153–156 (2021)

    2021

  193. [204]

    & Doyle, S

    Therrien, R. & Doyle, S. Role of training data variability on classifier performance and generalizability. in Medical Imaging 2018: Digital Pathology vol. 10581 58–70 (SPIE, 2018)

    2018

  194. [205]

    K., Pan, H

    Zhang, B., Qin, A. K., Pan, H. & Sellis, T. A Novel DNN Training Framework via Data Sampling and Multi-Task Optimization. in 2020 International Joint Conference on Neural Networks (IJCNN) 1–8 (2020). doi:10.1109/IJCNN48605.2020.9207329

    2020

Pith tools

Reviewed August 6, 2026 · model on record in the stance chip above.